Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Executive Summary
- Revive Therapeutics filed U.S. and Canadian national‑phase patent applications (PCT/CA2024/000008) covering “Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent.”
- The Company received Canadian Patent No. 3,172,170 for “Use of Bucillamine in the Treatment of Infectious Diseases,” strengthening exclusivity on its flagship asset.
- These IP developments broaden Revive’s strategic positioning in medical countermeasures and infectious‑disease markets, supporting future licensing, government procurement, and partnership opportunities.
Key Details
- Patent Filings – Nerve‑Agent Countermeasure
- U.S. application number: 19/518,001 (national phase of PCT/CA2024/000008).
- Canadian application number: 3,304,264 (national phase of the same PCT).
-
Covers compositions, methods and uses of bucillamine for victims exposed to chemical warfare agents.
-
Granted Patent – Infectious Diseases
- Canadian Patent No. 3,172,170 issued March 10, 2026; expires March 16, 2041.
-
Claims use of bucillamine in the treatment or prevention of infectious diseases (e.g., influenza, COVID‑19).
-
Strategic Implications
- Enhances Revive’s IP estate for bucillamine, a thiol‑based drug with >30 years clinical history in rheumatoid arthritis in Japan and South Korea.
- Positions the company to pursue government emergency‑preparedness programs, stockpiling contracts, and biodefense procurement related to nerve‑agent exposure.
-
Provides a solid foundation for future licensing or partnership discussions around viral and other infectious indications.
-
Collaboration with Defence R&D Canada – Suffield (DRDC)
-
Ongoing study evaluating bucillamine’s ability to mitigate nerve‑agent–induced brain injury; results expected soon, subject to DRDC authorization before release.
-
CEO Commentary
- Michael Frank highlighted the dual IP milestones as validation of bucillamine as a versatile platform asset with upside across therapeutic, public‑health and national‑preparedness markets.
Notable Quotes
“The grant of our Canadian patent for infectious diseases and the advancement of our nerve‑agent patent filings in the U.S. and Canada represent a major step forward for Revive and for the long‑term value of bucillamine.” – Michael Frank, CEO
“We believe Revive is building a highly strategic bucillamine franchise with meaningful upside… Bucillamine is not a one‑indication story – it is a platform opportunity.” – Michael Frank, CEO